



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Gefapixant (Standard)

<b>Cat. No.:</b>	HY-101588R
<b>CAS No.:</b>	1015787-98-0
<b>Molecular Formula:</b>	C <sub>14</sub> H <sub>19</sub> N <sub>5</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	353.4
<b>Target:</b>	P2X Receptor
<b>Pathway:</b>	Membrane Transporter/Ion Channel
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Gefapixant (Standard) is the analytical standard of Gefapixant. This product is intended for research and analytical applications. Gefapixant is an orally active and potent purinergic P2X <sub>3</sub> receptor (P2X <sub>3</sub> R) antagonist, with IC <sub>50</sub> values of ~30 nM versus recombinant hP2X <sub>3</sub> homotrimers and 100-250 nM at hP2X <sub>2/3</sub> heterotrimeric receptors. Gefapixant can be used for the research of chronic cough and knee osteoarthritis <sup>[1][2][3]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : ~30 nM (recombinant hP2X <sub>3</sub> homotrimers), 100-250 nM (hP2X <sub>2/3</sub> heterotrimeric receptors) <sup>[1]</sup> .

### REFERENCES

- [1]. Anthony P. Ford, et al. The therapeutic promise of ATP antagonism at P2X<sub>3</sub> receptors in respiratory and urological disorders. *Front Cell Neurosci.* 2013; 7: 267.
- [2]. Ford AP, In pursuit of P2X<sub>3</sub> antagonists: novel therapeutics for chronic pain and afferent sensitization. *Purinergic Signal.* 2012 Feb;8(Suppl 1):3-26.
- [3]. Martin Nguyen A, et al. Validation of a visual analog scale for assessing cough severity in patients with chronic cough. *Ther Adv Respir Dis.* 2021 Jan-Dec;15:17534666211049743.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA